Optimizing Risk Stratification in Portal Vein Thrombosis after Splenectomy and its Primary Prophylaxis with Antithrombin III Concentrates and Danaparoid Sodium in Liver Cirrhosis with Portal Hypertension
- 1 November 2014
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (5) , 865-874
Abstract
Decreased antithrombin III (ATIII) activity and large splenic vein diameter (SVD) are risk factors for portal vein thrombosis (PVT) after splenectomy in liver cirrhosis with portal hypertension. Antithrombin III concentrates can prevent PVT. This study was designed to stratify risks for PVT after splenectomy in cirrhotic patients and to develop prophylactic protocols for PVT. In 53 patients (testing cohort), the cutoff level of preoperative ATIII activity (≤60%) was evaluated for administration of ATIII concentrates. Antithrombin III activity and SVD were re-evaluated as criteria for prophylaxis of PVT. In 57 patients (validation cohort), the risk stratification of PVT and prophylactic protocols were validated. In the testing cohort, 10 (19%) of 53 patients had PVT. Risk level of PVT was stratified and prophylactic protocols were developed. Patients at low risk (ATIII activity ≥70% and SVD <10 mm) were not treated; those at high risk (ATIII activity <70% or SVD ≥10 mm) received ATIII concentrates (1,500 U/day) for 3 days; and those at highest risk (SVD ≥15 mm) received ATIII concentrates for 3 days, followed by danaparoid sodium (2,500 U/day) for 14 days and warfarin. In the validation cohort, 0 of 14 low-risk and 2 of 32 high-risk patients had PVT. Although 8 of 11 patients at highest risk had temporary PVT, it disappeared within 3 months postoperatively. Finally, only 2 (3.5%) of 57 patients had PVT. Risk stratification of PVT after splenectomy and prophylaxis with ATIII concentrates and danaparoid sodium dramatically reduced the incidence of PVT.Keywords
This publication has 28 references indexed in Scilit:
- Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein ThrombosisClinical Gastroenterology and Hepatology, 2012
- Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopeniaJournal of Gastroenterology and Hepatology, 2012
- The Coagulopathy of Chronic Liver DiseaseNew England Journal of Medicine, 2011
- Impact of Antithrombin III Concentrates on Portal Vein Thrombosis After Splenectomy in Patients With Liver Cirrhosis and HypersplenismAnnals of Surgery, 2010
- Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?HPB, 2009
- Technical standardization of laparoscopic splenectomy harmonized with hand-assisted laparoscopic surgery for patients with liver cirrhosis and hypersplenismJournal of Hepato-Biliary-Pancreatic Surgery, 2009
- First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patientsAmerican Journal of Hematology, 2006
- Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests†‡Hepatology, 2005
- Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosisJournal of Hepatology, 2004
- Splenectomy in patients with hepatocellular carcinoma and hypersplenism1Journal of the American College of Surgeons, 2000